Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Lumos Diagnostics Holdings Limited
  6. News
  7. Summary
    LDX   AU0000157091

LUMOS DIAGNOSTICS HOLDINGS LIMITED

(LDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

9,836,197 Ordinary Shares of Lumos Diagnostics Holdings Limited are subject to a Lock-Up Agreement Ending on 26-NOV-2021.

11/26/2021 EST

9,836,197 Ordinary Shares of Lumos Diagnostics Holdings Limited are subject to a Lock-Up Agreement Ending on 26-NOV-2021. These Ordinary Shares will be under lockup for 150 days starting from 29-JUN-2021 to 26-NOV-2021. Details: 40,124,915 shares held by Planet Innovation will be escrowed for the period of FY23 Results Release Time means 4.15pm on the date on which Lumos releases its preliminary results to ASX for the financial year ending 30 June 2023. 7,823,594 shares held by RPS Diagnostics will be escrowed for the period of FY22 Results Release Time means 4.15pm on the date on which Lumos releases its preliminary results to ASX for the financial year ending 30 June 2022. 7,823,595 shares held by RPS Diagnostics will be escrowed for the period of 1HFY22 Results Release Time means 4.15pm on the date on which Lumos releases its preliminary results to ASX for the financial year ending 30 December 2021. 9,836,197 shares held by Other Existing Securityholders will be escrowed for the period of FY22 Results Release Time means 4.15pm on the date on which Lumos releases its preliminary results to ASX for the financial year ending 26 November 2021. 9,836,197 Shares held by Other Existing Securityholders will be escrowed for the period of FY21 Results Release Time means 4.15pm on the date on which Lumos releases its preliminary results to ASX for the financial year ending 30 June 2021.


ę S&P Capital IQ 2021
All news about LUMOS DIAGNOSTICS HOLDINGS LIMITED
01/12Liverpool CCG and Community Pharmacy Liverpool Launch FebriDx« Service at More Than 100..
BU
01/11Lumos Diagnostics Launches Respiratory Infection Test in Liverpool, UK
MT
2021Lumos Diagnostics Begins Regulatory Submission Process for Rapid Antigen Test Kit
MT
2021Lumos Diagnostics Provides ViraDx Development and FebriDx Regulatory Update
CI
2021Lumos Diagnostics Secures Initial Orders for Rapid Antigen Test Kit in Canada
MT
2021Lumos Receives Initial Orders Worth Approximately USD 250,000 for CoviDx In Canada
CI
20219,836,197 Ordinary Shares of Lumos Diagnostics Holdings Limited are subject to a Lock-U..
CI
2021Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Tes..
BU
2021Canada Authorizes Use of Lumos Diagnostics' COVID-19 Rapid Antigen Test
MT
2021Lumos Diagnostics Holdings Limited Receives Authorization for CoviDxTM SARS-CoV-2 Rapid..
CI
More news
Financials
Sales 2022 25,7 M 18,5 M 18,5 M
Net income 2022 -13,4 M -9,66 M -9,66 M
Net cash 2022 19,9 M 14,3 M 14,3 M
P/E ratio 2022 -11,3x
Yield 2022 -
Capitalization 148 M 107 M 106 M
EV / Sales 2022 4,97x
EV / Sales 2023 3,28x
Nbr of Employees -
Free-Float -
Chart LUMOS DIAGNOSTICS HOLDINGS LIMITED
Duration : Period :
Lumos Diagnostics Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,98 AUD
Average target price 1,61 AUD
Spread / Average Target 64,3%
EPS Revisions
Managers and Directors
Robert P. Sambursky President, CEO, Executive Director & MD
Melanie Jaye Leydin Chief Financial Officer & Co-Secretary
Sam Lanyon Executive Chairman
Sacha Dopheide Chief Technology Officer
Jeffrey Bishop SVP-Research & Development
Sector and Competitors